Related Experiment Video
Updated: Aug 21, 2026
Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
Published on: November 10, 2017
Staurosporine-induced G2/M arrest in primary effusion lymphoma BCBL-1 cells
Yi-Fen Wang1, Yu-Fang Hsieh, Chin-Lin Lin
1Department of Medical Technology, Fooyin University, 151 Chin-Hsuen Road, Ta-Liao, Kaohsiung Hsien, Taiwan, Republic of China. yfwang@mail.fy.edu.tw
Abstract:
Staurosporine, an inhibitor of protein kinase C, is a potential antitumor drug and its derivatives are used as anticancer drugs in clinical trials. Human herpesvirus 8 (HHV-8) is implicated in all forms of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), indicating it to be a DNA tumor virus. It is difficult to culture cell lines derived from KS patients; we therefore used a cell line derived from PEL (BCBL-1) to investigate whether staurosporine affects the HHV-8-related tumors. Our results show that staurosporine treatment reduces the cell viability of BCBL-1 cells and causes cell cycle arrest in the G2/M phase. The G2/M arrest was associated with the decrease in the expression of Cdc2 and cyclin B. Furthermore, the induction of the HHV-8 lytic cycle was not observed under the staurosporine treatment.
Insights
Staurosporine, a protein kinase C inhibitor, reduced cancer cell viability and arrested the cell cycle in HHV-8-infected cells. This study found no induction of the human herpesvirus 8 (HHV-8) lytic cycle with staurosporine treatment.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Staurosporine is a protein kinase C inhibitor with potential antitumor properties.
- Human herpesvirus 8 (HHV-8) is associated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD).
- PEL cell lines, such as BCBL-1, serve as models for studying HHV-8-related malignancies due to difficulties in culturing KS-derived cells.
Purpose of the Study:
- To investigate the effects of staurosporine on HHV-8-infected PEL cells (BCBL-1).
- To determine if staurosporine influences cell viability, cell cycle progression, and HHV-8 lytic activity in these cells.
Main Methods:
- Treatment of BCBL-1 cells with staurosporine.
- Assessment of cell viability and cell cycle distribution.
- Analysis of Cdc2 and cyclin B expression.
- Monitoring for induction of the HHV-8 lytic cycle.
Main Results:
- Staurosporine treatment significantly reduced the viability of BCBL-1 cells.
- Staurosporine induced cell cycle arrest at the G2/M phase.
- This G2/M arrest correlated with decreased expression of Cdc2 and cyclin B.
- No induction of the HHV-8 lytic cycle was observed following staurosporine treatment.
Conclusions:
- Staurosporine exhibits cytotoxic effects on HHV-8-infected PEL cells.
- The drug-induced cell cycle arrest is mediated by the downregulation of key cell cycle regulators.
- Staurosporine does not appear to activate the HHV-8 lytic cycle, suggesting a potential for targeted therapy without viral reactivation.
